Paloma Partners’s Guardant Health GH Stock Holding History

Paloma Partners’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-115,300	Closed	-$2.38M	–	1327
2024 Q1	$2.38M	Buy	+115,300	New	+$2.47M	0.13%	215

Other funds holding GH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Paloma Partners's GH Position: Q3 2024 in Review

Paloma Partners sold out of Guardant Health (GH) in Q3 2024, closing a stake of 185 shares — an estimated $5.34K sold.

Paloma Partners first reported a position in GH in Q4 2019 and held it in 8 quarters. The position peaked at $2.29M in Q2 2021. 271 funds tracked by Wall St. Rank hold GH as of Q3 2024.

Paloma Partners reported no remaining Guardant Health position as of Q3 2024 after selling out during the quarter.
Paloma Partners sold 185 Guardant Health shares in Q3 2024, an estimated $5.34K.
Paloma Partners first reported a position in Guardant Health in Q4 2019 and held it in 8 quarters.
Paloma Partners's Guardant Health position peaked at $2.29M in Q2 2021.
271 funds tracked by Wall St. Rank held Guardant Health as of Q3 2024.

Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.